Grupo para la caracterización molecular de las neoplasias hematológicas
![Foto de Grupo para la caracterización molecular de las neoplasias hematológicas](/img/grupo.png)
![Foto de Hospital Universitario Araba](/img/noimage_org.png)
Hospital Universitario Araba
Vitoria, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Araba (15)
2024
-
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Blood Cancer Journal, Vol. 14, Núm. 1
2023
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
Journal of Clinical Medicine, Vol. 12, Núm. 20
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Leukemia and Lymphoma, Vol. 62, Núm. 12, pp. 2928-2938
-
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
PLoS ONE, Vol. 16, Núm. 9 September
-
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies
Blood Cancer Journal, Vol. 11, Núm. 12
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2019
-
Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain
ClinicoEconomics and Outcomes Research, Vol. 11, pp. 683-694
2013
-
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome
Leukemia Research, Vol. 37, Núm. 7, pp. 769-776
-
Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome
Journal of Clinical Oncology, Vol. 31, Núm. 7, pp. 916-922